Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 242


Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells.

Huang S, Sinicrope FA.

Mol Cancer Ther. 2010 Mar;9(3):742-50. doi: 10.1158/1535-7163.MCT-09-1004. Epub 2010 Mar 2.


BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells.

Huang S, Okumura K, Sinicrope FA.

Clin Cancer Res. 2009 Jan 1;15(1):150-9. doi: 10.1158/1078-0432.CCR-08-1575.


Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization.

Meng XW, Lee SH, Dai H, Loegering D, Yu C, Flatten K, Schneider P, Dai NT, Kumar SK, Smith BD, Karp JE, Adjei AA, Kaufmann SH.

J Biol Chem. 2007 Oct 12;282(41):29831-46. Epub 2007 Aug 13.


Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma.

Katz SI, Zhou L, Chao G, Smith CD, Ferrara T, Wang W, Dicker DT, El-Deiry WS.

Cancer Biol Ther. 2009 Dec;8(24):2406-16. Epub 2009 Dec 2.


Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3.

Yang F, Brown C, Buettner R, Hedvat M, Starr R, Scuto A, Schroeder A, Jensen M, Jove R.

Mol Cancer Ther. 2010 Apr;9(4):953-62. doi: 10.1158/1535-7163.MCT-09-0947. Epub 2010 Apr 6.


Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas.

Yang F, Van Meter TE, Buettner R, Hedvat M, Liang W, Kowolik CM, Mepani N, Mirosevich J, Nam S, Chen MY, Tye G, Kirschbaum M, Jove R.

Mol Cancer Ther. 2008 Nov;7(11):3519-26. doi: 10.1158/1535-7163.MCT-08-0138.


BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells.

Huang S, Sinicrope FA.

Cancer Res. 2008 Apr 15;68(8):2944-51. doi: 10.1158/0008-5472.CAN-07-2508.


Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2.

Blechacz BR, Smoot RL, Bronk SF, Werneburg NW, Sirica AE, Gores GJ.

Hepatology. 2009 Dec;50(6):1861-70. doi: 10.1002/hep.23214.


The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms.

Llobet D, Eritja N, Yeramian A, Pallares J, Sorolla A, Domingo M, Santacana M, Gonzalez-Tallada FJ, Matias-Guiu X, Dolcet X.

Eur J Cancer. 2010 Mar;46(4):836-50. doi: 10.1016/j.ejca.2009.12.025. Epub 2010 Jan 12.


Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.

Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, Vannini I, Silvestrini R, Zoli W.

J Cell Physiol. 2009 Jul;220(1):214-21. doi: 10.1002/jcp.21753.


Sorafenib induces apoptosis in HL60 cells by inhibiting Src kinase-mediated STAT3 phosphorylation.

Zhao W, Zhang T, Qu B, Wu X, Zhu X, Meng F, Gu Y, Shu Y, Shen Y, Sun Y, Xu Q.

Anticancer Drugs. 2011 Jan;22(1):79-88. doi: 10.1097/CAD.0b013e32833f44fd.


The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells.

Sung ES, Park KJ, Choi HJ, Kim CH, Kim YS.

Exp Cell Res. 2012 Aug 1;318(13):1564-76. doi: 10.1016/j.yexcr.2012.04.003. Epub 2012 Apr 10.


Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells.

Tai WT, Shiau CW, Chen HL, Liu CY, Lin CS, Cheng AL, Chen PJ, Chen KF.

Cell Death Dis. 2013 Feb 7;4:e485. doi: 10.1038/cddis.2013.18.


Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis.

Abdulghani J, Allen JE, Dicker DT, Liu YY, Goldenberg D, Smith CD, Humphreys R, El-Deiry WS.

PLoS One. 2013 Sep 26;8(9):e75414. doi: 10.1371/journal.pone.0075414. eCollection 2013.


Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells.

Taniai M, Grambihler A, Higuchi H, Werneburg N, Bronk SF, Farrugia DJ, Kaufmann SH, Gores GJ.

Cancer Res. 2004 May 15;64(10):3517-24.


BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing.

Martin AP, Park MA, Mitchell C, Walker T, Rahmani M, Thorburn A, Häussinger D, Reinehr R, Grant S, Dent P.

Mol Pharmacol. 2009 Aug;76(2):327-41. doi: 10.1124/mol.109.056309. Epub 2009 May 29.


Sorafenib inhibits endogenous and IL-6/S1P induced JAK2-STAT3 signaling in human neuroblastoma, associated with growth suppression and apoptosis.

Yang F, Jove V, Buettner R, Xin H, Wu J, Wang Y, Nam S, Xu Y, Ara T, DeClerck YA, Seeger R, Yu H, Jove R.

Cancer Biol Ther. 2012 May;13(7):534-41. doi: 10.4161/cbt.19603. Epub 2012 May 1.


HSP90 inhibitor NVP-AUY922 enhances TRAIL-induced apoptosis by suppressing the JAK2-STAT3-Mcl-1 signal transduction pathway in colorectal cancer cells.

Lee DH, Sung KS, Bartlett DL, Kwon YT, Lee YJ.

Cell Signal. 2015 Feb;27(2):293-305. doi: 10.1016/j.cellsig.2014.11.013. Epub 2014 Nov 18.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk